Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar plus TC vs TC in Advanced NSCLC
NCT00708812Phase 2Completed
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Jul 2007
- Primary completion
- Sep 2009
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of endostar in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoint: Progression-free Survival. Started Jul 2007; status: completed.
02
Drugs
endostar
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00708812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00708812.